Anaemia, renal insufficiency and cardiovascular outcome

Nephrology Dialysis Transplantation

Volumn 16, Issue SUPPL. 1, 2001, Pages 102-104

  Hegarty, J ^a   Foley, R N ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

Anaemia; Cardiovascular; Outcome; Renal insufficiency

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADAPTATION; ANEMIA; APOPTOSIS; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE MODEL; EXERCISE; EXPOSURE; HEART BLOOD VESSEL; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE FIBROSIS; HEART STRESS; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MEDICAL RESEARCH; MUSCLE CELL; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK MANAGEMENT; TIME;

EID: 0035013482     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.suppl_1.102     Document Type: Article

References (19)

1. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
2. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
3. Epidemiology of cardiovascular disease in chronic renal disease
4. Outcome and risk factors of ischemic heart disease in chronic uremia
5. Accelerated atherosclerosis in prolonged maintenance hemodialysis
6. Uremic cardiomyopathy: An inadequate left ventricular hypertrophy
7. The long-term evolution of uremic cardiomyopathy
8. Outcome and risk factors for left ventricular disorders in chronic uremia
9. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease
10. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease
11. Anemia in hemodialysis patients: Variables affecting this outcome predictor
12. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity-the experience of the Lombardy Dialysis Registry
13. Hematocrit level and associated mortality in hemodialysis patents
14. Hematocrit levels and hospitalization risks in hemodialysis patients
15. The effects of normal as compared with low hematocrit in patients with cardiac disease who are receiving hemodialysis and epoetin
16. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
17. Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients
18. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and hospitalizations
19. Signaling pathways for cardiac hypertrophy and cardiac failure